Evidence map›Paper›PMID 28218239›Full record

Trial reportLeukemia2017

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

A Hochhaus, T Masszi, F J Giles, J P Radich, D M Ross, M T Gómez Casares, A Hellmann, J Stentoft, E Conneally, V García-Gutiérrez and 10 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04043676 (Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response With Imatinib), which is not on this map. Cited by 148 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04043676 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response With Imatinib

TypeinterventionalSponsorFundación Teófilo Hernando, SpainRan2019 to 2023Enrolled40ConditionsChronic Myeloid LeukemiaArmsPonatinib
3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

A HochhausAbteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany.
T MassziDepartment of Haematology and Stem Cell Transplantation St István and St László Hospital, Budapest, Hungary.
F J GilesDevelopmental Therapeutics Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
J P RadichClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
D M RossSA Pathology, Adelaide, SA, Australia.
M T Gómez CasaresHospital Universitario Doctor Negrin, Las Palmas de Gran Canaria, Spain.
A HellmannMedical University of Gdańsk, Gdańsk, Poland.
J StentoftAarhus University Hospital, Aarhus, Denmark.
E ConneallySt James Hospital, Dublin, Ireland.
V García-GutiérrezServicio de Hematología, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.
N GattermannUniversitätsklinikum Düsseldorf, Düsseldorf, Germany.
W Wiktor-JedrzejczakMedical University of Warsaw, Department of Hematology, Warsaw, Poland.
P D le CoutreCharité Universitätsmedizin Berlin, Berlin, Germany.
B MartinoAzienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
S SausseleIII. Med. Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
H D MenssenNovartis Pharma AG, Basel, Switzerland.
W DengNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
N KrunicNovartis Institute for Biomedical Research, Cambridge, MA, USA.
V BedouchaNovartis Pharma AG, Basel, Switzerland.
G SaglioUniversity of Turin, Orbassano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR

Indexed as

AdultAgedAged, 80 and overFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedProtein Kinase InhibitorsPyrimidinesQuality of LifenilotinibProtein Kinase InhibitorsPyrimidines

Identifiers

PMID28218239
PMCPMC5508077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.